{"success":true,"data":{"pressRelease":{"id":"164302","rtpr_id":"nACSpgm1va-20261008","ticker":"STEK","exchange":"OTC","all_tickers":["STEK"],"title":"Physician Research Points to a New Frontier for Stemtech Corporation: Nutritional Activation of the Body's Endogenous Regenerative System","author":"ACCESSWIRE","published_at":"2026-10-08T12:30:00.386Z","article_body":"NAPLES, FL / ACCESS Newswire (https://www.accessnewswire.com/) / October 8,\n2026 / Stemtech Corporation (OTCID:STEK) today highlighted a new scientific\nresearch framework developed by Dr. Zahoorudin, MBBS, M.D., a board-certified\nDiplomate of the American Academy of Stem Cell Physicians (AASCP), USA,\nexploring how advances in regenerative biology could expand the scientific\nunderstanding behind Stemtech's pioneering stem cell nutrition platform.\n(https://app.accessnewswire.com/imagelibrary/2fa70165-8696-42f1-ba22-8e123d677081/image20261008002647vm11hw.png)\nStemtech was the pioneer company to focus on nutritional support for the\nbody's endogenous stem-cell system through the concept of Release →\nCirculate → Migrate. Dr. Zahoorudin's review suggests that modern research\nnow provides an opportunity to investigate this original concept at a much\ndeeper level-extending beyond bone-marrow mobilization to include nutrient\nsensing, mitochondrial biology, nitric-oxide signaling, circulating progenitor\ncells and tissue-resident regenerative niches.\n\n\"Stemtech was ahead of its time in recognizing that nutrition could interact\nwith the body's own regenerative biology. The next scientific question is no\nlonger only how many stem cells we can release from bone marrow. It is how\nnutrition may influence the entire regenerative environment-from cellular\nenergy and vascular signaling to mobilization, homing and the tissue niches\nwhere regeneration actually occurs\" said Dr. Zahoorudin.\n\nThe proposed model is supported by several emerging areas of research. Human\nstudies have reported increased circulating CD34+ progenitor cells and\nenhanced expression of the homing receptor CXCR4 following fucoidan ingestion.\nSeparately, dietary inorganic nitrate has been shown to increase circulating\nangiogenic/progenitor-cell populations, providing a potential biological\nconnection between nutrition, nitric oxide, vascular signaling and endogenous\nregenerative responses.\n\nAt the same time, modern regenerative biology demonstrates that the body\ncontains important tissue-resident regenerative populations outside the bone\nmarrow. Adipose tissue contains stromal and progenitor populations, while\nskeletal muscle contains satellite stem cells that participate directly in\nmuscle repair and adaptation. These findings support a broader research\nquestion: whether nutritional compounds can influence not only circulating\ncells but also the biological environments-or stem-cell niches-that regulate\nendogenous tissue renewal. Dr. Zahoorudin proposes that Stemtech's original\nmodel could therefore be confirmed through an expanded scientific sequence:\n\nACTIVATE → RELEASE → CIRCULATE → HOME → REGENERATE → RENEW\n(https://app.accessnewswire.com/imagelibrary/62f87782-20e1-4bdf-b381-b4b23159109a/image20261008002647aoufr4.png)\nUnderlying this model are pathways increasingly studied in metabolic, vascular\nand longevity science-including AMPK, SIRT1, PGC-1α, mitochondrial function,\neNOS/nitric oxide and SDF-1/CXCR4 signaling. Stemtech's existing nutritional\nportfolio already contains bioactive ingredients such as fucoidan,\nresveratrol, curcumin, Astragalus, Cordyceps, polyphenols and marine\nbotanicals, creating an opportunity for systematic research into how these\nformulations interact with contemporary markers of endogenous regenerative\nbiology.\n(https://app.accessnewswire.com/imagelibrary/833eb69b-1aef-43bb-9eca-48a1f835f41d/image20261008002647k486a3.png)\n\"The opportunity is not to replace Stemtech's original science, but to build\nupon it. Release, Circulation and Migration were the beginning. Modern science\nnow gives us the tools to investigate Activation, Homing, Vascular Signaling,\nCellular Energy and tissue-specific regenerative niches as parts of one\ninterconnected biological system.\" - Dr. Zahoorudin\n\nThe proposed framework represents a research direction rather than a\ntherapeutic claim. Dr. Zahoorudin emphasizes that effects on individual tissue\nstem-cell populations should be experimentally tested rather than assumed,\nwith future studies designed to determine which molecular pathways and\nregenerative cell populations are measurably influenced by specific\nnutritional formulations.\n\nThe research direction can be summarized in one concept:\n\nNUTRITIONAL ACTIVATION OF ENDOGENOUS REGENERATIVE BIOLOGY\n\nThis creates an extremely interesting research question for Stemtech:\n\nExercise / Fasting / Nutritional Signal → AMPK/SIRT1 → Lipolysis +\nAdipose-Niche Remodeling → CD34+ Adipose Progenitor Changes → Potential\nCell Trafficking?\n\nFor Stemtech, this represents an opportunity to connect its pioneering stem\ncell nutrition platform with the rapidly developing fields of metabolic\nsignaling, vascular regeneration, longevity biology and tissue-specific\nregenerative medicine and potentially define the next scientific chapter of\nstem cell nutrition.\n\n\"Stemtech was built on a simple but powerful idea: that nutrition can support\nthe body's own renewal system. Dr. Zahoorudin's work honors the Release →\nCirculate → Migrate science that defined our company, and it points us\ntoward the questions that can define our next chapter. We intend to continue\nto pursue this as a disciplined research direction-testing and measuring-so\nthat our distributors, customers and shareholders can be confident that the\nfuture of stem cell nutrition is being built on rigorous, credible science.\" -\nJohn W. Meyer, President & COO of Stemtech Corporation\n\nABOUT DR. ZAHOORUDIN\n\nDr. Zahoorudin, MBBS, M.D., a board-certified diplomate of the American\nAcademy of Stem Cell Physicians,(AASCP) USA, credits Stemtech's stem cell\nnutrition science with launching his career in regenerative medicine. He has\nused Stemtech stemceutical™ products in his clinical practice for over\nsixteen years and is on the Stemtech Life Sciences Advisory Board.\n\nABOUT STEMTECH\n\nStemtech Corporation is a publicly traded wellness company specializing in\nstemceuticals(™) - all-natural, plant-based nutritional solutions designed\nto support the body's natural regenerative processes. Founded in 2018,\nfollowing the acquisition of the operations from Stemtech International, Inc.,\n(established in 2005), the company has a long history of innovation in stem\ncell nutrition and wellness science.\n\nAs THE Pioneer in stem cell nutrition-spanning nutritional, skin care and,\nmore recently, pet health products-Stemtech is well positioned to grow within\nthe global wellness industry.\n\nStemtech's comprehensive product portfolio reflects its dedication to optimal\nhealth. Our all-natural innovations like stemrelease3(™) (supports the\nbody's natural regenerative signaling pathways), StemFlo(®) Advanced\n(supports circulation and normal cellular communication and tissue support\nprocesses), MigraStem(®) (supporting healthy aging and long-term vitality),\nand demonstrate the company's unwavering commitment to quality-of-life\nproducts and natural effectiveness. Cellect One(®) Shield: HOCL-a\nmultipurpose mist for skin care, cleaning, and disinfecting-and its\nintegration with the Cellect One(®) Rapid Renew Stem Cell Peptide Night Cream\n(featuring the patented QXP ingredient) underscore Stemtech's innovative edge\nin the beauty, health and wellness industry.\n\nFor 20 years, Stemtech has not only championed the benefits of natural,\nplant-based ingredients but has also led the way in scientific innovation\nwithin the wellness, anti-aging and longevity sectors. As industry forecasts\nand studies from reputable sources like the Global Wellness Institute project\nunprecedented growth, Stemtech's unwavering commitment to quality and\ninnovation ensures that they will remain at the forefront of this\ntransformative journey-making everyone healthier, while slowing down the aging\nprocess naturally.\n\nFORWARD LOOKING STATEMENTS\n\nThis announcement contains forward-looking statements within the meaning of\nthe \"safe harbor\" provisions of the U.S. Private Securities Litigation Reform\nAct of 1995. Such statements include, but are not limited to, those identified\nby words such as \"believes,\" \"will,\" \"expects,\" \"anticipates,\" \"estimates,\"\n\"intends,\" \"plans,\" \"targets,\" \"projects\" and similar expressions. The\nstatements in this release are based upon the current beliefs and expectations\nof our company's management and are subject to significant risks and\nuncertainties. Actual results may differ from those set forth in these\nforward-looking statements. Numerous factors could cause or contribute to such\ndifferences, including, but not limited to, the results of clinical trials\nand/or other studies, the challenges inherent in new product development\ninitiatives, the impact of any competitive products, our ability to license\nand protect our intellectual property, our ability to raise additional capital\nin the future, changes in government policy and/or regulation, potential\nlitigation by or against us, any governmental review of our products or\npractices, and other risks discussed from time to time in our filings with the\nSecurities and Exchange Commission. We undertake no obligation to update any\nforward-looking statements, or any information contained in this press release\nor in other public disclosures, at any time. Finally, the investing public is\nreminded that only announcements or information about Stemtech Corporation\ndisseminated by the Company and bearing its name are considered official.\n\nFor Investor Relations Information Contact:\n\nCEO Charles S. Arnold\nEmail: callcharlesarnold@gmail.com\nPhone: +1 336-918-0507\n\nStemtech Corporation\nPhone: +1 954-715-6000 ext 1040\nEmail: invrel@stemtech.com\n\nSOURCE: Stemtech Corporation\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/physician-research-points-to-a-new-frontier-for-stemtech-corporation-1234212)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSpgm1va-20261008","title":"Physician Research Points to a New Frontier for Stemtech Corporation: Nutritional Activation of the Body's Endogenous Regenerative System","author":"ACCESSWIRE","ticker":"STEK","created":"2026-10-08T12:30:00.386Z","tickers":["STEK"],"exchange":"OTC","article_body":"NAPLES, FL / ACCESS Newswire (https://www.accessnewswire.com/) / October 8,\n2026 / Stemtech Corporation (OTCID:STEK) today highlighted a new scientific\nresearch framework developed by Dr. Zahoorudin, MBBS, M.D., a board-certified\nDiplomate of the American Academy of Stem Cell Physicians (AASCP), USA,\nexploring how advances in regenerative biology could expand the scientific\nunderstanding behind Stemtech's pioneering stem cell nutrition platform.\n(https://app.accessnewswire.com/imagelibrary/2fa70165-8696-42f1-ba22-8e123d677081/image20261008002647vm11hw.png)\nStemtech was the pioneer company to focus on nutritional support for the\nbody's endogenous stem-cell system through the concept of Release →\nCirculate → Migrate. Dr. Zahoorudin's review suggests that modern research\nnow provides an opportunity to investigate this original concept at a much\ndeeper level-extending beyond bone-marrow mobilization to include nutrient\nsensing, mitochondrial biology, nitric-oxide signaling, circulating progenitor\ncells and tissue-resident regenerative niches.\n\n\"Stemtech was ahead of its time in recognizing that nutrition could interact\nwith the body's own regenerative biology. The next scientific question is no\nlonger only how many stem cells we can release from bone marrow. It is how\nnutrition may influence the entire regenerative environment-from cellular\nenergy and vascular signaling to mobilization, homing and the tissue niches\nwhere regeneration actually occurs\" said Dr. Zahoorudin.\n\nThe proposed model is supported by several emerging areas of research. Human\nstudies have reported increased circulating CD34+ progenitor cells and\nenhanced expression of the homing receptor CXCR4 following fucoidan ingestion.\nSeparately, dietary inorganic nitrate has been shown to increase circulating\nangiogenic/progenitor-cell populations, providing a potential biological\nconnection between nutrition, nitric oxide, vascular signaling and endogenous\nregenerative responses.\n\nAt the same time, modern regenerative biology demonstrates that the body\ncontains important tissue-resident regenerative populations outside the bone\nmarrow. Adipose tissue contains stromal and progenitor populations, while\nskeletal muscle contains satellite stem cells that participate directly in\nmuscle repair and adaptation. These findings support a broader research\nquestion: whether nutritional compounds can influence not only circulating\ncells but also the biological environments-or stem-cell niches-that regulate\nendogenous tissue renewal. Dr. Zahoorudin proposes that Stemtech's original\nmodel could therefore be confirmed through an expanded scientific sequence:\n\nACTIVATE → RELEASE → CIRCULATE → HOME → REGENERATE → RENEW\n(https://app.accessnewswire.com/imagelibrary/62f87782-20e1-4bdf-b381-b4b23159109a/image20261008002647aoufr4.png)\nUnderlying this model are pathways increasingly studied in metabolic, vascular\nand longevity science-including AMPK, SIRT1, PGC-1α, mitochondrial function,\neNOS/nitric oxide and SDF-1/CXCR4 signaling. Stemtech's existing nutritional\nportfolio already contains bioactive ingredients such as fucoidan,\nresveratrol, curcumin, Astragalus, Cordyceps, polyphenols and marine\nbotanicals, creating an opportunity for systematic research into how these\nformulations interact with contemporary markers of endogenous regenerative\nbiology.\n(https://app.accessnewswire.com/imagelibrary/833eb69b-1aef-43bb-9eca-48a1f835f41d/image20261008002647k486a3.png)\n\"The opportunity is not to replace Stemtech's original science, but to build\nupon it. Release, Circulation and Migration were the beginning. Modern science\nnow gives us the tools to investigate Activation, Homing, Vascular Signaling,\nCellular Energy and tissue-specific regenerative niches as parts of one\ninterconnected biological system.\" - Dr. Zahoorudin\n\nThe proposed framework represents a research direction rather than a\ntherapeutic claim. Dr. Zahoorudin emphasizes that effects on individual tissue\nstem-cell populations should be experimentally tested rather than assumed,\nwith future studies designed to determine which molecular pathways and\nregenerative cell populations are measurably influenced by specific\nnutritional formulations.\n\nThe research direction can be summarized in one concept:\n\nNUTRITIONAL ACTIVATION OF ENDOGENOUS REGENERATIVE BIOLOGY\n\nThis creates an extremely interesting research question for Stemtech:\n\nExercise / Fasting / Nutritional Signal → AMPK/SIRT1 → Lipolysis +\nAdipose-Niche Remodeling → CD34+ Adipose Progenitor Changes → Potential\nCell Trafficking?\n\nFor Stemtech, this represents an opportunity to connect its pioneering stem\ncell nutrition platform with the rapidly developing fields of metabolic\nsignaling, vascular regeneration, longevity biology and tissue-specific\nregenerative medicine and potentially define the next scientific chapter of\nstem cell nutrition.\n\n\"Stemtech was built on a simple but powerful idea: that nutrition can support\nthe body's own renewal system. Dr. Zahoorudin's work honors the Release →\nCirculate → Migrate science that defined our company, and it points us\ntoward the questions that can define our next chapter. We intend to continue\nto pursue this as a disciplined research direction-testing and measuring-so\nthat our distributors, customers and shareholders can be confident that the\nfuture of stem cell nutrition is being built on rigorous, credible science.\" -\nJohn W. Meyer, President & COO of Stemtech Corporation\n\nABOUT DR. ZAHOORUDIN\n\nDr. Zahoorudin, MBBS, M.D., a board-certified diplomate of the American\nAcademy of Stem Cell Physicians,(AASCP) USA, credits Stemtech's stem cell\nnutrition science with launching his career in regenerative medicine. He has\nused Stemtech stemceutical™ products in his clinical practice for over\nsixteen years and is on the Stemtech Life Sciences Advisory Board.\n\nABOUT STEMTECH\n\nStemtech Corporation is a publicly traded wellness company specializing in\nstemceuticals(™) - all-natural, plant-based nutritional solutions designed\nto support the body's natural regenerative processes. Founded in 2018,\nfollowing the acquisition of the operations from Stemtech International, Inc.,\n(established in 2005), the company has a long history of innovation in stem\ncell nutrition and wellness science.\n\nAs THE Pioneer in stem cell nutrition-spanning nutritional, skin care and,\nmore recently, pet health products-Stemtech is well positioned to grow within\nthe global wellness industry.\n\nStemtech's comprehensive product portfolio reflects its dedication to optimal\nhealth. Our all-natural innovations like stemrelease3(™) (supports the\nbody's natural regenerative signaling pathways), StemFlo(®) Advanced\n(supports circulation and normal cellular communication and tissue support\nprocesses), MigraStem(®) (supporting healthy aging and long-term vitality),\nand demonstrate the company's unwavering commitment to quality-of-life\nproducts and natural effectiveness. Cellect One(®) Shield: HOCL-a\nmultipurpose mist for skin care, cleaning, and disinfecting-and its\nintegration with the Cellect One(®) Rapid Renew Stem Cell Peptide Night Cream\n(featuring the patented QXP ingredient) underscore Stemtech's innovative edge\nin the beauty, health and wellness industry.\n\nFor 20 years, Stemtech has not only championed the benefits of natural,\nplant-based ingredients but has also led the way in scientific innovation\nwithin the wellness, anti-aging and longevity sectors. As industry forecasts\nand studies from reputable sources like the Global Wellness Institute project\nunprecedented growth, Stemtech's unwavering commitment to quality and\ninnovation ensures that they will remain at the forefront of this\ntransformative journey-making everyone healthier, while slowing down the aging\nprocess naturally.\n\nFORWARD LOOKING STATEMENTS\n\nThis announcement contains forward-looking statements within the meaning of\nthe \"safe harbor\" provisions of the U.S. Private Securities Litigation Reform\nAct of 1995. Such statements include, but are not limited to, those identified\nby words such as \"believes,\" \"will,\" \"expects,\" \"anticipates,\" \"estimates,\"\n\"intends,\" \"plans,\" \"targets,\" \"projects\" and similar expressions. The\nstatements in this release are based upon the current beliefs and expectations\nof our company's management and are subject to significant risks and\nuncertainties. Actual results may differ from those set forth in these\nforward-looking statements. Numerous factors could cause or contribute to such\ndifferences, including, but not limited to, the results of clinical trials\nand/or other studies, the challenges inherent in new product development\ninitiatives, the impact of any competitive products, our ability to license\nand protect our intellectual property, our ability to raise additional capital\nin the future, changes in government policy and/or regulation, potential\nlitigation by or against us, any governmental review of our products or\npractices, and other risks discussed from time to time in our filings with the\nSecurities and Exchange Commission. We undertake no obligation to update any\nforward-looking statements, or any information contained in this press release\nor in other public disclosures, at any time. Finally, the investing public is\nreminded that only announcements or information about Stemtech Corporation\ndisseminated by the Company and bearing its name are considered official.\n\nFor Investor Relations Information Contact:\n\nCEO Charles S. Arnold\nEmail: callcharlesarnold@gmail.com\nPhone: +1 336-918-0507\n\nStemtech Corporation\nPhone: +1 954-715-6000 ext 1040\nEmail: invrel@stemtech.com\n\nSOURCE: Stemtech Corporation\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/physician-research-points-to-a-new-frontier-for-stemtech-corporation-1234212)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T12:30:00.575628943Z","server_sent_at_ms":1791462600575},"received_at":"2026-10-08T12:30:00.741Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/physician-research-points-to-a-new-frontier-for-stemtech-corporation-1234212"},"analysis":{"id":"152725","press_release_id":"164302","analysis_json":{"industry":{"label":"Personal Care Products","sector":"Consumer Staples"},"redFlags":["Promotional science narrative with no data; research framework authored by a physician on Stemtech's own advisory board","Micro-cap OTC ticker; boilerplate caution on future capital raises and regulatory review"],"eventType":"other","narrative":"Stemtech highlighted a scientific research framework by Dr. Zahoorudin proposing to expand its stem-cell nutrition concept beyond Release-Circulate-Migrate to include nutrient sensing, mitochondrial biology and tissue regenerative niches.\n\nThe release explicitly frames this as a research direction rather than a therapeutic claim, with no clinical results, product approvals, or financial figures disclosed.\n\nDr. Zahoorudin sits on Stemtech's own Life Sciences Advisory Board and has used its products clinically for over sixteen years, so the endorsement is closely affiliated with the company.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Affiliated physician's speculative research framework -- no hard data, suppress or treat as noise."},"keyFigures":{},"quotedText":"Dr. Zahoorudin emphasizes that effects on individual tissue stem-cell populations should be experimentally tested rather than assumed","namedEntities":{"people":[{"name":"Dr. Zahoorudin","role":"physician, Stemtech Life Sciences Advisory Board member"},{"name":"John W. Meyer","role":"President & COO of Stemtech Corporation"},{"name":"Charles S. Arnold","role":"CEO, Investor Relations contact"}],"products":["stemrelease3","StemFlo Advanced","MigraStem","Cellect One Shield: HOCL","Cellect One Rapid Renew Stem Cell Peptide Night Cream","QXP"],"companies":[{"name":"Stemtech Corporation","ticker":"STEK","relationship":"filer"},{"name":"American Academy of Stem Cell Physicians (AASCP)","relationship":"professional body"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Promotional science-narrative release highlighting a third-party physician's research framework; explicitly states it is a research direction, not a therapeutic claim, with no trial results, revenue, or regulatory action."},"tickerRelevance":{"others":[],"primary":"STEK"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap OTC","dataContent":"none","eventGravity":"promotional-science-narrative","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Stemtech highlighted a scientific research framework by Dr. Zahoorudin proposing to expand its stem-cell nutrition concept beyond Release-Circulate-Migrate to include nutrient sensing, mitochondrial biology and tissue regenerative niches.\n\nThe release explicitly frames this as a research direction rather than a therapeutic claim, with no clinical results, product approvals, or financial figures disclosed.\n\nDr. Zahoorudin sits on Stemtech's own Life Sciences Advisory Board and has used its products clinically for over sixteen years, so the endorsement is closely affiliated with the company.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Zahoorudin","role":"physician, Stemtech Life Sciences Advisory Board member"},{"name":"John W. Meyer","role":"President & COO of Stemtech Corporation"},{"name":"Charles S. Arnold","role":"CEO, Investor Relations contact"}],"products":["stemrelease3","StemFlo Advanced","MigraStem","Cellect One Shield: HOCL","Cellect One Rapid Renew Stem Cell Peptide Night Cream","QXP"],"companies":[{"name":"Stemtech Corporation","ticker":"STEK","relationship":"filer"},{"name":"American Academy of Stem Cell Physicians (AASCP)","relationship":"professional body"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T12:30:07.671Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap OTC","dataContent":"none","eventGravity":"promotional-science-narrative","issuerAuthored":true}},"durationMs":6888,"modelName":"glm-5.3-flashx"}}